TICKERNERD
Menu
KTTAKTTAHealthcare · Biotechnology

KTTA Stock Forecast: Pasithea Therapeutics Corp. Price Predictions for 2026-2027

Last close, 28 Oct 2026
$0.39
−1.01% on the day

The 1 Wall Street analysts covering Pasithea Therapeutics Corp. hold a median 12-month price target of $3 — +663.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 16 of 100 as at 28 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$13.3M
Ticker Nerd rank
16/ 100
Median analyst target
$3.00
Analysts covering
1
Revenue$0.0
Operating income−$5.7M
Net income−$5.3M
Free cash flow−$4.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−19.5%
1M
−18.1%
YTD
−69.5%
1Y
−45.6%
From 52W high
−73.3%
From 52W low
+34.6%
$0.29
$1.47
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

KTTA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Pasithea Therapeutics Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 28 Oct 2026
16/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
90
Revisions
55
Accruals
39
Issuance
29
Growth
27
Quality
22
Volatility
14
Momentum
13
Value
5

Size (90): Smaller than most of the companies we track.

Value (5): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

KTTA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KTTA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.50$1.00$1.50$2.00$2.50$3.00Jan 26Apr 26Jul 26Oct 26KTTAHigh $3.00Median $3.00Low $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $3.00Median $3.00High $3.00

The green dot is the last close — the median target sits +663.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
16 June 2026HC Wainwright & Co.ReiteratesBuy$3.00
16 June 2026HC Wainwright & Co.ReiteratesBuy—
20 Apr 2026HC Wainwright & Co.ReiteratesBuy—
8 Dec 2025HC Wainwright & Co.InitiatesBuy—
10 July 2023EF HuttonReiteratesBuy$2.00
1 June 2023EF HuttonAssumesBuy$2.00
3 Apr 2023EF HuttonMaintainsBuy$2.30 → $2.00
14 Dec 2021EF HuttonInitiatesBuy$3.25

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

KTTA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

KTTA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 28 Oct 2026, Pasithea Therapeutics Corp. returned −45.6% against +13.6% for the S&P 500, dividends included.

KTTA vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140160180Jan 26Apr 26Jul 26Oct 26KTTAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

KTTA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Pasithea Therapeutics Corp. (KTTA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.1×

Cheaper than 78% of US stocks

Price / sales
—
Price / book
0.3×

Cheaper than 87% of US stocks

EV / EBITDA
1.7×

Cheaper than 57% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−65.5%

Higher than 18% of US stocks

Return on assets
−36.0%

Higher than 12% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Pasithea Therapeutics Corp. (KTTA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Pasithea Therapeutics Corp. has a market value of $13.3M and an enterprise value of −$32.4M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$21.3M.

  • Free cash flow in the twelve months to 30 June 2026: −$17.8M.

  • Shares outstanding: 33.4M.

  • Trailing P/E: −0.1×; forward P/E: −0.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Pasithea Therapeutics Corp. employs 5 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 28 Oct 2026

Data provided by Twelve Data

Peers

KTTA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
KTTAPasithea Therapeutics Corp.$13.3M16
DAREDaré Bioscience, Inc.$13.2M30
CNSYCerenome, Inc.$13.2M16
AZRAdial Pharmaceuticals, Inc.$13.3M21
TCRXTScan Therapeutics, Inc.$13.0M55
PBMPsyence Biomedical Ltd.$13.0M4
BOLTBolt Biotherapeutics, Inc.$12.6M87

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Pasithea Therapeutics Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest KTTA news & analysis

Pasithea Therapeutics to Host Virtual KOL Event on NF1 Treatment November 4, 2026

GlobeNewsWire · 28 Oct 2026neutral

Pasithea Therapeutics announced a virtual KOL event titled “Rethinking NF1 Treatment: KOL Perspectives on Cutaneous and Plexiform Neurofibromas,” scheduled for November 4, 2026, at 11:00 a.m. ET. The company is developing PAS-004 for chronic diseases including NF1-associated neurofibromas.

Why it matters — The event will provide KTTA watchers with an opportunity to hear perspectives on NF1 treatment from key opinion leaders.

Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026

GlobeNewsWire · 23 Oct 2026positive

Pasithea Therapeutics reported positive Phase 1 data for PAS-004 in advanced cancer, describing prolonged stable disease in a heavily pre-treated population. Four patients remained on treatment for more than 300 days, including two who continued once-daily treatment for over 500 days; the company also characterized the overall safety profile as favorable.

Why it matters — The reported duration of treatment and tolerability findings are relevant to KTTA watchers following PAS-004’s clinical development.

Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference

GlobeNewsWire · 14 Sept 2026positive

Pasithea Therapeutics announced that it will present initial Part A clinical data from its ongoing Phase 1/1b trial of PAS-004 in adults with NF1 at the 2026 European Neurofibromatosis Conference in Vienna, Austria, from November 12–14, 2026. The company was selected for an oral presentation on cutaneous neurofibromas data and a poster presentation on plexiform neurofibromas data.

Why it matters — KTTA watchers would care because this marks the first disclosure of PAS-004 clinical data from the ongoing Phase 1/1b study in NF1 patients, providing an early read on the drug candidate's development progress.

Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences

GlobeNewsWire · 3 Sept 2026neutral

Pasithea Therapeutics announced it will participate in two investor conferences in September 2026: holding one-on-one investor meetings at the 12th Annual Cantor Global Healthcare Conference (September 9-11) and presenting at the H.C. Wainwright 28th Annual Global Investment Conference (September 14-16).

Why it matters — A KTTA watcher would care because these engagements signal the company's effort to increase its visibility with healthcare investors leading into the fall of 2026.

FAQ

Frequently asked questions about KTTA stock

What is the KTTA stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Pasithea Therapeutics Corp. have a median 12-month price target of $3, with estimates ranging from $3 to $3. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KTTA stock a buy right now?

Of the 1 analysts covering Pasithea Therapeutics Corp., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Pasithea Therapeutics Corp. 16 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KTTA?

As at 28 Oct 2026, Pasithea Therapeutics Corp. ranks 16 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (90 of 100).

Will KTTA stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +663.4% from the last close, and Ticker Nerd's factor model ranks Pasithea Therapeutics Corp. 16 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KTTA stock forecast for 2030?

No analyst covering Pasithea Therapeutics Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KTTA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $3 over the next 12 months.

How has KTTA stock performed over the past year?

Pasithea Therapeutics Corp. returned -45.6% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Pasithea Therapeutics Corp. do?

Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system disorders and RASopathies.

What is the latest news on KTTA?

The most recent item we track (GlobeNewsWire, 28 Oct 2026): "Pasithea Therapeutics to Host Virtual KOL Event on NF1 Treatment November 4, 2026". Pasithea Therapeutics announced a virtual KOL event titled “Rethinking NF1 Treatment: KOL Perspectives on Cutaneous and Plexiform Neurofibromas,” scheduled for November 4, 2026, at 11:00 a.m. ET. The company is developing PAS-004 for chronic diseases including NF1-associated neurofibromas.

Company

About Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system disorders and RASopathies. The company’s current programs center on PAS-004, a next-generation macrocyclic MEK inhibitor being developed for indications that include neurofibromatosis type 1-associated plexiform neurofibromas and selected oncology uses. Pasithea Therapeutics Corp. also works on additional therapeutic candidates aimed at neurological and psychiatric conditions, reflecting a broader emphasis on diseases with significant unmet medical need. The company operates through therapeutic development activities and clinic-related services, positioning itself across both drug research and patient-facing healthcare applications. Based in Miami Beach, Florida, Pasithea Therapeutics Corp. plays a role in the clinical-stage biotechnology market by advancing targeted treatment candidates for complex disorders.

CEO Dr. Tiago Reis Marques M.D., Ph.D. · 5 employees · United States · https://www.pasithea.com